Bordetella pertussis is an obligate human respiratory pathogen that causes the disease whooping 17 cough. A whole cell vaccine (DTP) was developed in the 1940s and was subsequently replaced 18 in the 1990s with a protein-based subunit acellular vaccine (DTaP; tdap). Today, we are 19 observing a resurgence of whooping cough due to evolution of the pathogen and waning vaccine 20 immunity. The use of vaccines decreased the need for basic research on this pathogen. As a 21 result, numerous questions on the basic pathogenesis of B. pertussis remain to be answered. 22
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Introduction 38
Bordetella pertussis is a bacterial respiratory pathogen and the causative agent of whopping 39 cough or pertussis. While whopping cough is a vaccine-preventable disease, the number of cases 40 have risen during the past decade (1). Re-emergence of pertussis is a multi-factorial problem that 41 highlights the need to re-design and improve current vaccination strategies. Historically, whole 42 cell vaccines (WCV), made of formalin inactivated bacteria were first introduced in the 1940s. 43
Following implementation of WCV, efforts by multiple research teams led to the identification of 44 B. pertussis major virulence factors, the adenylate cyclase toxin (ACT) and pertussis toxin (PT) 45
(2). The global regulatory system of virulence genes (Bordetella virulence genes system or Bvg) 46 was discovered (3, 4) and important surface adhesins such as the filamentous hemagglutinin 47 (FHA), fimbriae, and pertactin (PRN) were identified. This knowledge led to the development of 48 acellular vaccines which are composed of PT, FHA, fimbriae, and PRN (5). Since the 49 implementation of acellular vaccination against pertussis, research efforts on the pathogenesis 50 and basic bacteriology of Bordetella pertussis have decreased. As a result, there are still very 51 important gaps in the knowledge of how the bacterium causes infection. These gaps need to be 52 filled to rationally design the next generation of pertussis vaccines. 53
Recent advances in sequencing technology have opened new doors to study bacterial 54 pathogenesis using a global transcriptomics approach. In a previous study, we demonstrated the 55 feasibility of sequencing bacterial RNA in complex samples (6). We were able to isolate both 56 bacterial and host RNA during an acute murine pneumonia, and perform dual-seq to determine 57 both transcriptional profiles during infection. In the present study, we hypothesized that this 58 methodology could be applied for the study of other bacterial pathogens such as Bordetella 59 pertussis. Here, we describe the first transcriptome of B. pertussis during lung infection and 60 identify some of the technical pitfalls of this approach for tissues in which the bacterial burden is 61 low. To circumvent these technical difficulties, we propose a novel methodology to facilitate 62
The reads were aligned to the B. pertussis Tohama I genome (11) using CLC Genomics 113 Workbench version 9.5. Reads per kilobase per million (RPKM) and fold change for each gene 114 were calculated. Approximately 180,000-200,000 reads mapped per 100 million 2x50bp samples. 115
Upon inspection of the reads, we observed cross mapping reads that are likely due to the 116 presence of residual murine RNA in the sample. To avoid non-specific mapping and remove 117 these reads, we increased mapping stringency to 100% identity and extracted only reads that 118 mapped as pairs and counted them as fragments. These manipulations removed ~90% of the 119 total reads. Due to the low number of total reads obtained from the lungs of infected mice, we 120 sampled in vitro grown RNAseq reads from 10 million 2x50bp down to 15,000 total reads. Fold 121 change was calculated by comparison of the in vitro UT25 B. pertussis reads to the in vivo NSG 122 mouse UT25 reads. The raw data reads will soon be submitted to the Sequence Read Archive 123 (SRA). If requested, we would also be happy to provide the raw reads directly. bronchiseptica, E. coli, and P. aeruginosa were grown in the culture conditions described above. 128
Various amounts from OD600 0.3 to OD600 0.003 were filtered through 5 µm syringe filters 129 (Sartorius Minisart part ref 17594 Cellulose Acetate). The input culture and outflow were plated 130 on agar plates (BG or LA) to determine the amount of input and flow through bacteria. To isolate 131 bacteria from the infected mouse lungs, mice were dissected and the lungs were extracted and 132 placed into 1 ml of PBS. The lungs were then homogenized with glass Dounce tissue grinders 133 (Sigma-Aldrich). The homogenate was then strained through a 70 µm nylon cell strainer (VWR). 134
The filtrate was then passed through a 5 µm syringe filter. The suspension was next pelleted by 135 16,100 x g for 4 min in 1.5 ml Eppendorf tubes. The supernatant was then discarded, RNAprotect 136 bacterial reagent (Qiagen) was added to the pellet, and samples were stored at -80°C. 137
RNA isolation and reverse transcriptase PCR (qRT-PCR). 139
For qRT-PCR analysis, cells stored at -80°C in RNAprotect (Qiagen) were lysed with lysozyme, 140 and RNA was isolated using the RNAsnap method (12). Briefly, cell pellet were resuspended in 141 RNA extraction solution (18mM EDTA, 0.025% SDS, 1% 2-mercaptoehanol, 95% formamide) by 142 vortexing vigorously. Samples were incubate at 95°C for 7 min and pelleted by centrifugation at 143 16,000g for 5 min at room temperature. The supernatant containing RNA was then pipetted into 144 a fresh tube without disturbing the clear gelatinous pellet, and DNA and RNA concentrations were 145 measured using a Qubit 3.0 fluorometer. After extraction, DNA was digested using an off-column 146 digestion with RNase-free DNase and re-isolated with another RNeasy column. RNA 147 concentration and quality was assessed on a Molecular Devices i3 Spectramax Spectra drop 148 plate and on a Qubit 3.0 fluorometer. To ensure RNA was DNA-free, 25 ng of RNA was checked 149
by PCR amplification and was only used for cDNA if no amplicon was observed and a CT of >32. electrophoresis were performed on all reactions. Gene expression was normalized to the rpoB 158 reference using the 2 -∆∆CT method (13). For statistical analysis, the ∆CT for the three biological 159 replicate experiments was calculated and a Student's t-test was performed using Microsoft Excel 160 2013. Standard error of mean was calculated based on the variability of the ∆CT of three biological 161
replicates. For the rpoB to Gapdh absolute quantitation PCR, amplicons of rpoB and Gapdh were 162 generated, purified and quantified. The number of copies per ng of DNA was determined and 163 standard curves were generated for rpoB (5x10 8 copies to 500) and Gapdh (4.4x10 8 to 440 164 copies) with three technical replicates. Microsoft Excel was used to plot standard curves based 165 on the CTs of the known standards described above and number of copies in each sample was 166 calculated using a linear regression with R 2 values of 0.999 for both rpoB and Gapdh. The ratio 167 of Gapdh to rpoB RNA was used to estimate the relative amount of host to pathogen RNA in each 168 sample. The following primers sequences used in this study were described by Bibova et al. (14) : 169
(GCTGGGACCCGAGGAAAT), rpoBR (CGCCAATGTAGACGATGCC). BP2497 were designed 174 in a previous study:
BP2497F (TCGGATCGCACCAATTACTTC) and BP2497R 175 (CCTTGGCGATCAGCGAGTT) (10). The following primers were used for Gapdh: gapdhf 176 (CATGGCCTTCCGTGTTCCT) and gapdhr (GCGGCACGTCAGATCCA). 177
Results and Discussion 179
Establishment of a murine model to perform in vivo transcriptomic analysis of B. pertussis. 180
The main objective of this study was to perform RNA sequencing on B. pertussis during lung 181 infection. Our previous studies with the respiratory pathogen P. aeruginosa demonstrated the 182 feasibility of sequencing both bacterial and host pathogen during infection. However, they also 183 highlighted the need to use high bacterial loads (10 8 to 10 9 CFU/organ) to obtain sufficient RNA 184 for purification and analysis. In addition, our previous attempts to perform RNAseq from CD1 185 mouse trachea yielded very few reads of bacterial RNA, demonstrating the challenge of these 186 types of workflows. Therefore, in this work, we first optimized the murine model of pertussis to 187 maximize the recovery of bacteria during infection. To this end, we performed intranasal infections 188 of outbred CD1 mice (traditional model used for vaccine development) and in immunodeficient 189 NSG mice. We hypothesized that immunodeficient mice would be unable to clear bacterialinfection and have higher bacterial burdens in the airways which would increase the recovery rate 191 of bacterial RNA for sequencing. Mice were infected with 10 7 CFU/mouse (CD1) or 4x10 6 192 CFU/mouse (NSG) and euthanized 24 or 72 hr post infection. Bacterial burden was determined 193 in the nasal passages by performing a nasal wash, and in the trachea and lung by generating 194 tissue homogenates. As expected, significantly higher bacterial burden was observed in the nasal 195 wash, trachea, and lung of NSG mice compared to CD1 mice (Fig. 1) . The bacterial burden in the 196 nasal wash and lung remained constant between day 1 and 3 in CD1 mice, and even significantly 197 decreased in the trachea (Fig. 1) . However, bacterial burden significantly increased over time in 198 NSG infected mice in both the upper and the lower respiratory airways (Fig 1) . Overall, the lung 199 samples of NSG mice at the later time point had the highest bacterial burden. Therefore, for 200 subsequent experiment, the lungs from NSG mice infected with B. pertussis strain UT25 were 201 harvested two days post infection and used for RNA preparation for NGS. genome for each sample. Upon inspection of the reads, it was apparent that the mouse RNA of 209 the sample was cross mapping to the bacterial genome. This non-specific cross-mapping was 210 due to sequence similarities between the bacterial and the murine genomes. In order to focus on 211 only true B. pertussis reads, we extracted only the reads that mapped with 100% identity in pairs. 212
This removed the false positive mappings as observed in Fig. 2 . However, this procedure also 213 significantly decreased the number of B. pertussis reads. Therefore, we sampled the in vitro UT25 214 reads down to 15,000 to allow for a more accurate comparison to the NSG mouse B. pertussis 215 of B. pertussis, which is insufficient for high quality transcriptome analysis. The murine reads 217 greatly outnumbered the pathogen reads (Table 1) . We were able to detect up to 828 genes with 218 at least 1 true B. pertussis read. When we compared the in vitro and in vivo B. pertussis reads 219 (Table 2) , we observed promising data suggesting that the changes in gene expression observed 220 in these samples are relevant for the pathogenesis of B. pertussis. We performed String analysis 221 to better understand the associations between the genes differentially regulated between the two 222 datasets (Fig. 3) . In this analysis, we observed the alcaligin siderophore biosynthesis genes in 223 the infected NSG lungs (Table 2 and Fig. 3A) . Alcaligin is a siderophore that sequesters iron for 224 the pathogen and is an important factor required for infection. We also detected fhaB in the 225 infected lung tissue. FhaB is an adhesin that allows B. pertussis to adhere to the airway during 226
infection. In previous experiments we observed that fhaB is one of the most abundant transcripts 227 in the transcriptome (10). We also detected both pertussis and adenylate cyclase toxin transcripts 228 in the infected lung tissue (Table 2) . Overall in this limited analysis, B. pertussis gene expression 229 was higher in vitro. It is likely that B. pertussis grows faster in vitro and is transcriptionally more 230 active (Fig. 3B) . From this analysis, we concluded that method optimization to enrich the RNA of 231 B. pertussis was required in order to characterize the in vivo transcriptome of the bacterium in the 232
mouse. 233 234
Method optimization for the extraction of bacterial RNA using differential filtration. Despite 235 murine model optimization to maximize bacterial RNA recovery the total number of reads from 236 bacterial RNA remained low. To increase bacterial sequence coverage without rising sequencing 237 cost by increasing the total number of sequencing lanes and total reads, we developed a novel 238 methodology to separate bacterial from eukaryotic RNA. This method is based on the difference 239 in size between bacterial and eukaryotic cells present in lung homogenates. We first performed 240 method optimization using in vitro grown bacterial samples of E. coli, P. aeruginosa, B. 241 bronchiseptica, and B. pertussis. In vitro grown cultures of various bacterial pathogens werefiltered through a 5 µm filter, and plated before and after filtration to estimate percentage recovery 243 of the bacteria. Overall, 30 to 60% of the bacteria present in the suspension were recovered after 244
filtration (Figure 4). Recovery rate was different between the species, with B. bronchiseptica 245
showing the highest recovery rate and P. aeruginosa the lowest. These differences are potentially 246 due to the variation in size of these bacteria, P. aeruginosa cells measuring up to 3µm in length, 247
while Bordetellae cells measure less than 0.7 µm in length. From these results, we concluded that 248 5 µm filters could be used to recover a significant number of bacteria from suspensions. 249
250
Method optimization for the extraction of bacterial RNA from infected tissue. In the next 251 phase of our protocol development, we applied filtration to homogenized tissue to separate 252 bacterial cells from the rest of the homogenate. Infected tissues were first gently homogenized 253 using a mechanical Dounce glass homogenizer to separate the cells in the lung while causing 254 minimal cell lysis compared to enzymatic digestion. Homogenates were then filtered through a 70 255 µm filter to remove large clumps and debris. The resulting filtrate was pushed through a 5 µm 256 filter to remove eukaryotic cells. This second filtrate, containing bacteria and residual eukaryotic 257 DNA released from cell lysis during homogenization, was then centrifuged to pellet bacteria. The 258 bacterial pellet was finally re-suspended in RNA protect and processed for extraction (Fig. 5) . 259
Bacterial loads in nasal wash, trachea and lung were quantified in the tissue homogenate and in 260 the final bacterial pellet after filtration (Fig. 6) . From these data, we estimated the range of viable 261 bacteria needed for RNAseq analysis. We estimate that RNA from 10 4 B. pertussis CFU is the 262 minimum that can be used for in vivo seq (assuming 100% of the sample is pathogen). This 263 estimation is based on our filtration method and RNA purification using RNAsnap, and assumes 264 that the RNA obtained is DNA-free. For samples in which these yields cannot be achieved, low 265 input kits such as the Nugen Ovation RNAseq V2 library preparation kit can be used to perform 266 the analysis with picogram amounts of RNA. 267 qPCR estimation of rpoB to Gapdh transcript levels. To sequence the transcriptome of B. 269 pertussis during infection, it is important to have a high bacteria to host RNA ratio in the sample. 270
To estimate this ratio, we performed absolute qPCR to count the numbers of transcripts in cDNA 271 samples from the B. pertussis infected NSG mice (Fig. 7) . We added this quality control metric 272 to select samples with high amounts of bacterial RNA that have the best probability of successful 273 RNAseq analysis. Standard curves of rpoB and Gapdh templates were generated and used to 274 calculate rpoB and Gapdh transcript copy numbers. We observed that not all samples had the 275 same pathogen to host copy ratios (Fig. 7) . However, the data suggested that in most samples 276 there was a 1:4 ratio of rpoB to Gapdh. We also filtered a B. pertussis infected CD1 lung and 277 observed a similar rpoB to Gapdh ratio. This promising data suggests that we can obtain sufficient 278 RNA, even from mice that are not highly susceptible. infected NSG lung samples ( Fig. 6 and 8) . We selected the cya and ptx genes that encode the 284 major toxins as well as fhaB, bvgA, and BP2497. We hypothesized that the expression of the 285 genes encoding these toxins would be more highly expressed in the mouse compared to in vitro. 286
We observed increased cya and ptx gene expression in all of our NSG mice (Fig. 8) . Expression 287 of fhaB, the major adhesin, was decreased in vivo compared to in vitro. The genes cya and ptx 288 are classified as "class II Bvg system genes" (3) whereas fhaB is a "class I gene". Class I genes 289 are usually expressed at different levels than class II genes, which could explain why cya, ptx and 290 fhaB are differentially regulated. In addition, it is possible that the bacteria tightly adhered to 291 epithelial cells during infection are not collected using this purification method, which would 292 introduce bias and explain differences in gene expression involved in bacterial adhesion. This 293 caveat will be further investigated as the project moves forward. At this phase, we are most 294 interested in successfully performing the feasibility of performing in vivo RNAseq on B. pertussis 295 in the murine lung. 296 297 298
Conclusions 299
In this report, we have detailed our progress on developing RNAseq workflows to characterize 300 the transcriptome of B. pertussis infecting the murine lung. Bacterial pathogens are small yet can 301 cause substantial harm to the host. B. pertussis releases toxins which block or suppress both the 302 innate and adaptive immune responses. These toxins are essential to infection but little is known 303 about the roles of the majority of the genes encoded in the genome of B. pertussis. We 304 hypothesize that the B. pertussis transcriptome in vivo will be significantly different than the in 305 vitro transcriptome in media such as on BG or SSM. It is possible genes that are highly expressed 306 during infection could be exploited as vaccine antigens. By answering the simple question of 307 "what does the pathogen express when it infects?", we believe that significant advancement can 308 be made which will potentially impact vaccines and treatments. Our initial attempts showed that 309 performing dual-seq on a pathogen that is both growing slowly and is present in at low levels in 310 tissue samples is challenging. These technical difficulties led us to re-formulate our ideas and 311 come up with an innovate strategy. By combining a novel filtration method to separate the bacteria 312 from host tissue and exhaustive qRT-PCR quality controls, we have obtained RNA with a 313 pathogen to host ration high enough to perform RNAseq in the near future. Next generation 314 sequencing applications such as RNAseq have greatly expanded over the past few years but we 315 believe there is still a need to further develop RNA preparation workflows to truly take advantage 316 of these technologies. There are many other bacterial pathogens for this type of methodology 317 could potentially be applied. We envision that this strategy could also be used in other models 318 systems such as the baboon model of pertussis. We hypothesize that depending on the lower 319 limits of detection, it may also be possible to isolate pathogens directly from human patients anddetermine the "human specific" transcriptomes of the pathogen. Our current goal is to fully 321 characterize the transcriptome of the human pathogen B. pertussis and we will also seek to apply 322 this strategy to other pathogens and extend our knowledge of how pathogens infect. lung samples prepared by the filtration protocol were compared to the SSM control data. Genes 500 encoding the adenylate cyclase toxin (cya) and the pertussis toxin (ptxA) were increased in vivo 501 compared to in vitro. The bvgA and fhaA genes were slightly decreased in expression. BP2497 502 encodes a putative protease and it was also decreased in the murine lung. Data from three 503 biological replicates with three technical replicates each. Standard deviations are calculated from 504 variations between biological replicates and compared using a t-test (* p<0.05; *** p<0.001). 505 506 507 508 509
